{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-22-000044","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.411665+00:00","generated_at":"2026-06-26T01:37:04.851866+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nautilus Biotechnology Q1 net loss widens to $15.8M on higher R&D and G&A costs","bullets":["Operating expenses $16.0M, up 90% YoY from $8.4M, driven by headcount and public company costs.","Net loss $15.8M vs $8.4M in prior year; no revenue reported (pre-revenue proteomics platform).","Cash, cash equivalents, and investments $349.0M as of March 31, 2022.","Scientific progress: manuscript on single-molecule protein arrays, Genentech collaboration results, and AACR antibody data."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-22-000044","json":"https://secwatch.observer/filing/0001808805-22-000044.json","markdown":"https://secwatch.observer/filing/0001808805-22-000044.md","text":"https://secwatch.observer/filing/0001808805-22-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000044/0001808805-22-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000044/naut-20220503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:37:04.851866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}